Mesoblast (NASDAQ:MESO) Stock Price Expected to Rise, Piper Sandler Analyst Says

Mesoblast (NASDAQ:MESO) had its price objective hoisted by Piper Sandler from $11.00 to $15.00 in a research report released on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other research firms have also issued reports on MESO. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, September 24th. Jefferies Financial Group upgraded Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Mesoblast currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Mesoblast Stock Down 12.7 %

Shares of NASDAQ MESO opened at $14.63 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a 1-year low of $1.61 and a 1-year high of $19.15. The stock has a fifty day simple moving average of $10.48 and a two-hundred day simple moving average of $8.29.

Institutional Trading of Mesoblast

Large investors have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in Mesoblast in the second quarter valued at approximately $562,000. XY Capital Ltd purchased a new stake in shares of Mesoblast during the 3rd quarter valued at $244,000. Jane Street Group LLC lifted its holdings in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after acquiring an additional 26,959 shares during the last quarter. Creative Planning purchased a new position in Mesoblast in the third quarter worth $147,000. Finally, XTX Topco Ltd bought a new position in Mesoblast in the second quarter valued at $103,000. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.